Pliant Therapeutics IncPLRX
Price$1.05

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $0TTM through 30 Jun 2026
Net Income -$149.3MTTM through 30 Jun 2026
Free Cash Flow -$70.9MTTM through 30 Jun 2026

Margins

Current
Gross Margin0.0%

Returns

-101.6%ROE
-78.7%ROA

Balance Sheet Health

Debt / Equity0.00x
Current Ratio12.00x
Net Debt-$170.9Mnet cash position
Cash & Equivalents$24.9M

Quality Metrics

Altman Z-Score-7.45
Piotroski F-Score2 / 9
Earnings-Beat Rate75.0%

Multi-Year Trend

Revenue
'19'20'21'22'23'24'25
FY2025: $0
Diluted EPS-$1.50TTM
'19'20'21'22'23'24'25
FY2025: $-2.43

Dividend

No dividend

Capital Allocation

R&D Spend$63.8M

Segment Performance

No segment data available.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.